Does the Crowded TNF Market Really Need Two New Agents? Rheumatologists Provide Insight in the Wave One Report of LaunchTrends™: SIMPONI and CIMZIA
New BioTrends Report Explores Anticipated Treatment Pattern Shifts Expected with the Proposed Bundled Payment Structure Planned for 2011
Use of Takeda’s ULORIC On The Rise According to Latest BioTrends Report
BioTrends Announces a New Syndicated Report Series, LaunchTrendsTM: Feraheme
Once Monthly Dosing: How Much of a Competitive Advantage is it? Rheumatologists Provide Insight in the Baseline Report of LaunchTrends™: SIMPONI™
Read more...
Page 10 of 17
